TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30854571

Group type: EXPERIMENTAL
Intervention: Light blue gel nail polish using Masimo oximeter
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Orange gel nail polish using Masimo oximeter
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pink gel nail polish using Philips oximeter
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Black gel nail polish using Philips oximeter
Number of subjects: 17
Study: 30327407

Group type: EXPERIMENTAL
Intervention: Namaste Care Family programme
Number of subjects: 0
Study: 27271828

Group type: EXPERIMENTAL
Intervention: Authors' physical rehabilitation program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group rehabilitation program (recommended scheme)
Number of subjects: 60
Study: 24932893

Group type: EXPERIMENTAL
Intervention: Text message plus call
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Call
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Text message
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control
Number of subjects: 242
Study: 22699097

Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) program, constraint of the unaffected hand for 6 hours per day, duration of 2 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) program
Number of subjects: 23
Study: 20115970

Group type: EXPERIMENTAL
Intervention: Negative pressure dressing (NPD)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Static pressure dressing (SPD)
Number of subjects: 54
Study: 18797097

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) + alpha-tocopherol (AT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (OCC patients)
Number of subjects: 89
Study: 16418113

Group type: EXPERIMENTAL
Intervention: Multi-sensory stimulation (experimental group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy, full-term males
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy, full-term females
Number of subjects: 26
Study: 11836286

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily for 3 months, followed by 20 mg daily for 3 months)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg and 20 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10094169

Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg b.i.d. IV/IM initially, decreasing over 40 days) with antituberculosis treatment
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group (antituberculosis treatment only)
Number of subjects: 178
Study: 7593627

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (increasing concentrations); no deep inspirations allowed
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine (increasing concentrations); deep inspirations initiated
Number of subjects: 20

Group type: COMPARATOR
Intervention: Forced expirations from a normal end‐tidal inspiration
Number of subjects: 20
Study: 2119303

Group type: EXPERIMENTAL
Intervention: Discontinuation of phenytoin (PHT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Discontinuation of carbamazepine (CBZ)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Discontinuation of valproate (VPA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (continued existing therapy)
Number of subjects: 58
Study: 31926883

Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole (TMP-SMZ) 160 mg/800 mg twice daily for 45 days followed by 1 dose every other day for 311 days
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo (starch tablet) every other day for 311 days
Number of subjects: 141
Study: 31835508

Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise training program (3 times per week for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (maintained regular lifestyle)
Number of subjects: 20
Study: 27859395

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid at a dosage of 10 mg/kg, administered 4-9 hours preoperatively
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid at a dosage of 1 mg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid at a dosage of 10 mg/kg, administered 3-14 hours preoperatively
Number of subjects: 26
Study: 25886987

Group type: EXPERIMENTAL
Intervention: Videos of walking people
Number of subjects: 0

Group type: COMPARATOR
Intervention: Videos of nature
Number of subjects: 0
Study: 23906938

Group type: EXPERIMENTAL
Intervention: mTOR inhibitor everolimus (n=16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Calcineurin inhibitor and/or mycophenolate sodium (n=20)
Number of subjects: 36
Study: 21244500

Group type: EXPERIMENTAL
Intervention: 50% autologous bone (AB) to 50% anorganic bovine bone (ABB) ratio (Group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 20% autologous bone (AB) to 80% anorganic bovine bone (ABB) ratio (Group 2)
Number of subjects: 28
Study: 19728118

Group type: COMPARATOR
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 1775
Study: 17367093

Group type: EXPERIMENTAL
Intervention: AVINZA (morphine sulfate extended-release capsules)
Number of subjects: 266

Group type: COMPARATOR
Intervention: OxyContin (oxycodone hydrochloride controlled-release tablets)
Number of subjects: 266
Study: 14644065

Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg, intramuscular injection)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11555829

Group type: EXPERIMENTAL
Intervention: Adipose free tissue (AFT) modeled as a nonlinear function of body weight.
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Maximal AFT determined by both sex and height.
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Nonlinear model for AFT and body weight relationship.
Number of subjects: 273
Study: 9692412

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 31
Study: 7922932

Group type: EXPERIMENTAL
Intervention: Systematic intervention by a geriatric internist or psychiatrist and follow-up by a liaison nurse
Number of subjects: 88

Group type: COMPARATOR
Intervention: Regular medical care (Control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Systematic intervention
Number of subjects: 88
Study: 2468862

Group type: EXPERIMENTAL
Intervention: 5 mg nitrendipine (sublingually)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine (sublingually)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine (intravenously)
Number of subjects: 45
Study: 30554386

Group type: EXPERIMENTAL
Intervention: Jump rope exercise program (EX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 40
Study: 27832384

Group type: EXPERIMENTAL
Intervention: Topiroxostat 160 mg/day
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg/day
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157

Group type: COMPARATOR
Intervention: Allopurinol 200 mg/day
Number of subjects: 157
Study: 25963425

Group type: EXPERIMENTAL
Intervention: SOX plus bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab
Number of subjects: 0
Study: 24117062

Group type: EXPERIMENTAL
Intervention: IRT‐TCM (n = 46)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional rehabilitation techniques (n = 23)
Number of subjects: 69
Study: 22141217

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with 0.1% bupivacaine at a rate of 10 mL/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous epidural analgesia with 0.1% bupivacaine in continuous infusion at a rate of 8 mL/h
Number of subjects: 40
Study: 18038208

Group type: EXPERIMENTAL
Intervention: PTVE (2-octyl cyanoacrylate)
Number of subjects: 102

Group type: COMPARATOR
Intervention: EVL (endoscopic band ligation)
Number of subjects: 102
Study: 16839319

Group type: EXPERIMENTAL
Intervention: Bremelanotide (20 mg, single intranasal dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12571655

Group type: EXPERIMENTAL
Intervention: 6 g American ginseng (AG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10636260

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 80
Study: 9374924

Group type: EXPERIMENTAL
Intervention: Progressive strength training for 6 months
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Detraining after strength training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Habitual physical activities (Control group)
Number of subjects: 39
Study: 1608219

Group type: EXPERIMENTAL
Intervention: Lipostabil treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 23
Study: 3910730

Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Combination of piperacillin, netilmicin and cefotaxime
Number of subjects: 50
Study: 30452747

Group type: EXPERIMENTAL
Intervention: Audiologist-guided Internet-based cognitive behavioral therapy (iCBT) for tinnitus
Number of subjects: 104
Study: 28950859

Group type: EXPERIMENTAL
Intervention: Hip arthroscopy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Physiotherapy-led non-surgical management (Personalised Hip Therapy - PHT)
Number of subjects: 140
Study: 25669177

Group type: EXPERIMENTAL
Intervention: Early adenotonsillectomy (eAT)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: eAT
Number of subjects: 464
Study: 23303043

Group type: EXPERIMENTAL
Intervention: TC-5619 (1 mg day 1 to week 4, 5 mg week 4 to 8, and 25 mg week 8 to 12)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: TC-5619
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 21502757

Group type: EXPERIMENTAL
Intervention: ER‐DP plus ASA
Number of subjects: 1294

Group type: COMPARATOR
Intervention: ASA
Number of subjects: 1294
Study: 19105416

Group type: EXPERIMENTAL
Intervention: Velcade therapy
Number of subjects: 36
Study: 16406171

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of split, trivalent influenza vaccine
Number of subjects: 720

Group type: COMPARATOR
Intervention: Subcutaneous injection of split, trivalent influenza vaccine
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of split, trivalent influenza vaccine (females)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Subcutaneous injection of split, trivalent influenza vaccine (females)
Number of subjects: 720
Study: 15592191

Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.74 mg/kg) sestamibi imaging
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intracoronary Doppler
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sestamibi imaging
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sestamibi imaging and intracoronary Doppler
Number of subjects: 14
Study: 11405162

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary training & treatment course (ISBP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study: 9262208

Group type: EXPERIMENTAL
Intervention: Stationary textured background
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moving textured background (opposite direction to target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moving textured background (same direction to target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-field stationary backgrounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-field moving background (opposite direction to target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small-field moving background (same direction to target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large-field backgrounds
Number of subjects: 0
Study: 8499536

Group type: EXPERIMENTAL
Intervention: Personal dietary counselling with a standard diet and fortnightly appointments
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with standard diet explanation and appointments at 2 and 4 months
Number of subjects: 64
Study: 3691273

Group type: EXPERIMENTAL
Intervention: Intravenous cisapride 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cisapride 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cisapride (5 mg, 10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous cisapride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral cisapride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30067631

Group type: EXPERIMENTAL
Intervention: Im-Bessel correlated beam generated via coherent modes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27694590

Group type: EXPERIMENTAL
Intervention: Kinematic alignment (KA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Mechanical alignment (MA)
Number of subjects: 71
Study: 24211316

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1200mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22261836

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic rendezvous (LERV) technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2-stage approach (preoperative ERCP followed by laparoscopic cholecystectomy)
Number of subjects: 100
Study: 20040335

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a dose of 2 ‐ 3.5 g/m(2)
Number of subjects: 118
Study: 18344711

Group type: EXPERIMENTAL
Intervention: Risk models specific to ethnicity, gender, and Apolipoprotein E genotype developed for the trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk assessment protocols sensitive to implications of genetic testing for multiple ethnic groups.
Number of subjects: 0
Study: 15971275

Group type: EXPERIMENTAL
Intervention: NicQb vaccine
Number of subjects: 32
Study: 11208501

Group type: EXPERIMENTAL
Intervention: Cladribine treatment (2.1 mg/kg b.w. administered in 7 cycles for 12 months)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cladribine treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 34
Study: 9042823

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (5 x 500 U epoetin beta/kg body weight intravenously over a 14-day period before surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9508938

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate dentifrice
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional dentifrice
Number of subjects: 156
Study: 3234245

Group type: EXPERIMENTAL
Intervention: Lorazepam (0, 1.5, 3 and 6 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diazepam (0, 10, 20 and 40 mg)
Number of subjects: 14
Study: 29536782

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of oxycodone (Group O)
Number of subjects: 162

Group type: COMPARATOR
Intervention: 1 µg/kg of fentanyl (Group F)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Saline (Group S)
Number of subjects: 162
Study: 27334434

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233 mg zinc gluconate containing 30 mg zinc) for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (233 mg zinc gluconate)
Number of subjects: 40
Study: 23269105

Group type: EXPERIMENTAL
Intervention: Sertraline (flexible-dose, target dose 200 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21655893

Group type: EXPERIMENTAL
Intervention: Posterior cruciate‐sacrificing mobile‐bearing prosthesis
Number of subjects: 107

Group type: COMPARATOR
Intervention: Posterior‐stabilized mobile‐bearing prosthesis
Number of subjects: 107
Study: 19454920

Group type: EXPERIMENTAL
Intervention: Family-focused therapy for adolescents (FFT-A)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 58
Study: 17436601

Group type: COMPARATOR
Intervention: 200 IU/day rFSH
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose step-up OI protocol with weekly increments of 25 IU/day rFSH
Number of subjects: 0

Group type: COMPARATOR
Intervention: 150 IU/day rFSH
Number of subjects: 0
Study: 15545098

Group type: EXPERIMENTAL
Intervention: Botox injections (18 units per area) with ablative laser resurfacing
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline placebo injections with ablative laser resurfacing
Number of subjects: 33
Study: 11384635

Group type: EXPERIMENTAL
Intervention: 250 microg recombinant hCG (rhCG)
Number of subjects: 198

Group type: COMPARATOR
Intervention: 5,000 IU urinary hCG (uhCG)
Number of subjects: 198
Study: 9141121

Group type: EXPERIMENTAL
Intervention: Prosthesis with 907 grammes mass added
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prosthesis with 454 grammes mass added
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prosthesis without mass added
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-amputee control with mass added
Number of subjects: 20
Study: 7526065

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Felodipine 20 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 3415888

Group type: EXPERIMENTAL
Intervention: Fentanyl by patient controlled analgesia (PCA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline by infusion pump plus morphine 10 mg/70 kg s.c. (Control)
Number of subjects: 16
Study: 29047215

Group type: EXPERIMENTAL
Intervention: 103 mg of p-synephrine (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 233 mg of caffeine + 104 mg of p-synephrine (LC + S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 240 mg of caffeine (LC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 337 mg of caffeine + 46 mg of p-synephrine (HC + S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 325 mg of caffeine (HC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28198729

Group type: EXPERIMENTAL
Intervention: Land exercise (107 women)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Water exercise (49 women)
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Land + water exercise (101 women)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control group (311 women)
Number of subjects: 568
Study: 26755464

Group type: EXPERIMENTAL
Intervention: Combined Coping Skills Training (CST) and Pharmacotherapy (Ph)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pharmacotherapy (Ph) alone
Number of subjects: 35
Study: 23338669

Group type: EXPERIMENTAL
Intervention: CID (Child Incentive Delay)
Number of subjects: 30

Group type: COMPARATOR
Intervention: MID (Monetary Incentive Delay)
Number of subjects: 30
Study: 21235403

Group type: EXPERIMENTAL
Intervention: Behavioral interventions to improve ART adherence
Number of subjects: 204

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 204
Study: 18447091

Group type: EXPERIMENTAL
Intervention: Breathing Awareness Meditation (BAM), 10-minute sessions daily for three months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 66
Study: 22686429

Group type: EXPERIMENTAL
Intervention: DEH (dehydration with no fluid intake)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CON (rehydration with fluid intake)
Number of subjects: 13
Study: 16286955

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 70
Study: 14579656

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) nasal spray for 2 weeks
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Dimethindene maleate (DMM) nasal spray
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 9686728

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin treatment for Ureaplasma urealyticum colonized infants.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Noncolonized infants (control group).
Number of subjects: 124
Study: 7649339

Group type: EXPERIMENTAL
Intervention: 60 mg nicergoline, orally, daily for 6 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 1.8-6 mg co-dergocrine mesylate, orally or intramuscularly, daily for 6 months
Number of subjects: 57
Study: 2916716

Group type: EXPERIMENTAL
Intervention: Simulation games including role‐playing/group dynamics and modeling/training
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 136
Study: 1106204

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-estrogen contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estrogen-free contraceptives
Number of subjects: 0
Study: 30067590

Group type: EXPERIMENTAL
Intervention: Activity and Motivation in Physical EDucation intervention
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1173
Study: 28210777

Group type: EXPERIMENTAL
Intervention: Biperiden (2.0 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of biperiden and ATD
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 25175303

Group type: EXPERIMENTAL
Intervention: 1:1 mesh graft
Number of subjects: 72

Group type: COMPARATOR
Intervention: sheet graft
Number of subjects: 72
Study: 22906434

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lying back position
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 94